United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer. bySoujanya RaviFebruary 7, 2026